Blade therapeutics pipeline
WebSep 25, 2024 · About Blade Therapeutics Blade Therapeutics is a private, clinical-stage biopharmaceutical company advancing novel anti-fibrotic therapies to meet important … WebNov 9, 2024 · Blade Therapeutics has agreed to merge with Biotech Acquisition Company, a publicly traded special purpose acquisition company, or SPAC, affiliated with SPRIM Global Investments, which raised $230 million in its initial public offering in January 2024. Photo: Wendye Robbins, president and CEO of Blade
Blade therapeutics pipeline
Did you know?
WebSep 5, 2024 · Blade’s focused approach offers the potential to produce disease-modifying, life-saving therapies. Blade expects to advance a differentiated pipeline of oral, small-molecule therapies that include a non-competitive autotaxin inhibitor and an inhibitor of dimeric calpains. Visit www.blademed.com for more information and follow Blade on … WebSep 25, 2024 · About Blade Therapeutics Blade Therapeutics is a private, clinical-stage biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs. Blade’s lead compound, BLD-2660, is a highly selective calpain inhibitor targeted for the treatment of chronic fibrotic diseases.
WebDec 15, 2024 · The two top executives at Blade Therapeutics appear to no longer be with the biotech after the startup failed to merge with its SPAC partner earlier this year. ... Founded in 2015, Blade built a pipeline of oral, small molecule drugs that it hoped would treat idiopathic pulmonary fibrosis, liver and cardiac fibrosis, as well as Huntington’s ... WebSep 25, 2024 · SOUTH SAN FRANCISCO, Calif.-- ( BUSINESS WIRE )--Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced the acquisition of ATXCo, Inc.,...
WebOct 14, 2024 · Blade expects to advance a differentiated pipeline of oral, small-molecule therapies that include a non-competitive autotaxin inhibitor and inhibitors of dimeric calpains designed for potential... WebBlade Therapeutics is a discovery stage drug development company. Their mission is to create antifibrotic treatment strategies that address a wide variety of congenital and …
WebMar 22, 2024 · Blade is advancing a robust pipeline of potential first-in-class investigational therapies for diseases of lung, liver and heart fibrosis, as well as neurodegenerative diseases. This includes...
WebBlade Therapeutics is advancing a differentiated pipeline of oral, small-molecule therapies that include a non-competitive autotaxin inhibitor and inhibitors of dimeric calpains for the … Blade Therapeutics is advancing innovative anti-fibrotic therapies to meet currently … boots my store netWeb2 days ago · Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s diverse pipeline is comprised of highly differentiated, potentially best-in-class or first-in-class proprietary small molecule compounds aimed at addressing clinically … boots my perfect eyes creamWebOct 1, 2024 · Blade Therapeutics will expand its pipeline in the field of fibrotic diseases with the acquisition of Atxco and its lead candidate PAT-409, which is ready to enter Phase 1 clinical studies. PAT-409 was engineered to specifically inhibit the autotaxin enzyme involved in the production of a fatty molecule called lysophosphatidic acid, ... boots my purchasingWebNov 30, 2024 · About Blade Therapeutics Blade Therapeutics, Inc. is a biopharmaceutical company focused on developing cutting-edge treatments for ... Blade expects to … hathway broadband plans in noidaWebNov 8, 2024 · Blade Therapeutics Chief Executive Officer Wendye Robbins noted that the proposed merger with Biotech Acquisition Company would advance the company’s mission to bring life-changing treatments to patients with devastating diseases. Blade is aiming to advance a differentiated pipeline of small-molecule therapies with disease modifying … boots mytime loginWebNov 8, 2024 · Wendye Robbins, M.D., president and CEO of Blade and a board nominee of the combined company, said, "We view Blade's science as world-class, with a clinical-stage pipeline targeting diseases that ... boots mytime log inWebApr 6, 2024 · Blade Therapeutics: ClinicalTrials.gov Identifier: NCT04334460 Other Study ID Numbers: B-2660-204 : First Posted: April 6, 2024 Key Record Dates: Results First … boots my time